Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379:111-121.

Published: 17th September 2018

Authors: Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al.

Conclusion

This trial included over then thousand women with ER positive, HER-2 negative breast cancer. Endocrine therapy alone was not inferior: hazard ratio for disease recurrence, second primary or death 1.09, 95 per cent confidence interval 0.94 to 1.24. Chemotherapy may benefit women aged 50 and under.

Pubmed Link

Your comments

0 Comments